1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Generic Drug Opportunity Assessment : Apixaban (Eliquis)

Generic Drug Opportunity Assessment : Apixaban (Eliquis)

  • January 2014
  • -
  • Greystone Research Associates

Greystone Research has identified a branded drug that represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy. Details of our findings are contained in an insightful assessment, the highlights if which are presented below.

The Brand

Eliquis (apixaban) is an oral Factor Xa inhibitor – essentially an anticoagulant - targeting stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic (VTE) disorders. It is currently approved in the EU, Canada and Japan for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors and for use in VTE prevention in adult patients who have undergone elective hip or knee surgery. In December 2012, the U.S. Food and Drug Administration (FDA) approved Eliquis to reduce the risk of stroke and systemic embolism in patients with NVAF.

The Drug

Apixaban is one of a group of novel oral anticoagulants (NOACs) that are more convenient, and are at least equally effective and safer (regarding bleeding complications) for stroke prevention compared with vitamin K antagonists (VKAs).

The Market

Atrial fibrillation (AF) increases the risk of stroke. The degree of increase can be substantial, depending on the presence of additional risk factors (such as high blood pressure). Atrial fibrillation may be treated with medications to either slow the heart rate to a normal range (rate control) or revert the heart rhythm to normal (rhythm control). The prevalence of AF in a population increases with age, with 8% of people over 80 having AF. Chronic AF leads to a small increase in the risk of death. Nonvalvular atrial fibrillation is AF in the absence of rheumatic mitral valve disease, a prosthetic heart valve, or mitral valve repair.

Patents & Exclusivity

The composition of matter patent covering apixaban in the U.S. expires in February 2023(excluding potential patent term extensions) and in the EU it expires in 2022. The Company has applied for supplementary protection certificates. Some of these supplementary protection certificates have been granted and expire in 2026. Data exclusivity in the EU expires in 2021. The composition of matter patent expires in Canada in 2022. Eliquis has been granted exclusivity by the FDA under the exclusivity code NCE (New Chemical Entity). This exclusivity expires on December 24, 2017. The FDA is precluded by law to approve any ANDA prior this date.

Therapeutic Sector P (IV) Activity

Until recently, the cardiovascular drug sector has been quite active with regard to ANDA filings, with P (IV) certifications averaging about five per year since 2006 - 2010. This trend reflects the fragmented therapeutic environment. We expect the rate of P (iV) certifications to increase through 2018, as brand drugs lose exclusivity and patent protection.

Market Dynamics

In terms of the overall market growth for novel oral anticoagulants, we expect Eliquis to overtake Pradaxa as the overall market segment leader in 2016. We are also forecasting total global Eliquis revenue to exceed US $4 billion for the year 2017. The result will be a highly attractive generic market for the ANDA first-filer prepared to enter the market at the end of 2017 when the FDA exclusivity period for Eliquis is scheduled to expire.

Generic Revenue Opportunity

We are predicting that the ANDA first-filer entering the market in will capture of the total global market for apixaban drugs for the treatment of AF in calendar year . The majority of sales will come during the 180-day exclusivity period, at a price approximately of the brand price.

Report Highlights

Eliquis – The Brand
Apixaban – The Market
Apixaban – The Opportunity
Manufacturing and Sourcing
Eliquis Patents and Exclusivity
Therapeutic Class P4 Certifications
Generic 1st-to-File Revenue Opportunity
Business Risk Assessment
First-to-File – Probabilistic Scenario

Table Of Contents

Generic Drug Opportunity Assessment : Apixaban (Eliquis)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.